Phathom Pharmaceuticals Inc
PHAT
Get informed when a big investor buys or sells
+ FollowMarket Cap$764.86M
Close$
$-4.09
140.6% downside
Current Fair Value
140.6% downsideOvervalued by 140.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $764.86 Million |
|---|---|
| Enterprise Value | $586.58 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.03 |
| Beta | 0.57 |
| Outstanding Shares | 82,050,618 |
Return
| Return on Equity | -36.89% |
|---|---|
| Return on Assets | 40.73% |
| Return on Invested Capital | 128.21% |
Valuation & Multiples
| P/E Ratio | -5 |
|---|---|
| PEG | - |
| Price to Sales | 5.05 |
| Price to Book Ratio | -2.02 |
| Enterprise Value to Revenue | 2.86 |
| Enterprise Value to EBIT | 2.54 |
| Enterprise Value to Net Income | 4 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | -0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.28
Average shareholder expectationRevenue Estimate
$58.84 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.20
Average shareholder expectationRevenue Estimate
$74.30 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0577▲ 0.37% |
|---|---|
| Total Calls | 1,047,900▲ 16.78% |
| Total Puts | 60,500▲ 24.74% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 94.47%▲ 10.05% |
|---|---|
| Total Invested | $763.62M▼ 25.54% |
| Investors Holding | 179▲ 1.00% |
ESG Score
No data
About Phathom Pharmaceuticals Inc
55 employeesPhathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, E...